RxDoctor Payments Data

Melissa Myers, MD

Psychiatry · Conway, NHNPI 1689794604

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 65.0% of it on its own, with 5 other manufacturers making up the rest. 2024 is the largest year on record at $171, 4.3 times the $39 reported in 2019.

$531in general payments, 2019–2025

Across 27 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$346
  • E.r. Squibb & Sons, L.L.C.$45
  • Teva Pharmaceuticals USA, Inc.$40
  • Alkermes, Inc.$36
  • Takeda Pharmaceuticals U.S.A., Inc.$34
  • Johnson & Johnson$31

What the payments were for

  • Food & beverage$531100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$531 in reported general payments places this provider in the 70th percentile of 166 psychiatry providers in New Hampshire.

See all psychiatry providers in New Hampshire

Medicare billing

Part B allowed, 2024
$57,088
Medicare patients
143
Services billed
574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate52$179,954
VraylarCariprazine Hcl37$85,195
AustedoDeutetrabenazine26$77,125
Abilify MaintenaAripiprazole17$51,210
Clozapine89$8,361
TrintellixVortioxetine Hydrobromide15$7,134
Aripiprazole24$7,088
Atomoxetine Hcl24$2,357
Quetiapine Fumarate44$2,229
Divalproex Sodium24$1,992
Olanzapine30$1,701
Venlafaxine Hcl ErVenlafaxine Hcl20$1,086
Oxcarbazepine25$874
Divalproex Sodium ErDivalproex Sodium25$827
Benztropine Mesylate36$638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$31$179,95452 claims
AbbVieVraylar$346$85,19537 claims
Teva Pharmaceuticals USA, Inc.Austedo$40$77,12526 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$34$7,13415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 166 psychiatry providers in New Hampshire.

Other psychiatry in Conway

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →